학술논문
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement
Document Type
Article
Source
(2024): 1-13.
Subject
Language
Korean
ISSN
20050380
Abstract
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort tostandardize and enhance the quality of domestic uterine corpus cancer treatment bydeveloping updated clinical practice guidelines in 2021. The KSGO revised the guidelinesbased on a literature search using 4 key elements: Population, Inter vention, Comparison,and Outcome framework. These elements include the evaluation of the efficacy and safety ofimmune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patientswho have failed platinum-based chemotherapy, as well as the effect of combined treatmentwith trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally,the guideline assessed the efficacy and safety of omitting lymph node dissection in low-riskendometrial cancer patients, investigated the effect of sentinel lymph node mapping inearly-stage endometrial cancer surger y, addressed the outcome of chemoradiation therapy asa postoperative treatment in patients with advanced (stage III–IVA) endometrial cancer, andexplored the impact of initial treatment with immune checkpoint inhibitors on sur vival inpatients with advanced or recurrent endometrial cancer patients.
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort tostandardize and enhance the quality of domestic uterine corpus cancer treatment bydeveloping updated clinical practice guidelines in 2021. The KSGO revised the guidelinesbased on a literature search using 4 key elements: Population, Inter vention, Comparison,and Outcome framework. These elements include the evaluation of the efficacy and safety ofimmune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patientswho have failed platinum-based chemotherapy, as well as the effect of combined treatmentwith trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally,the guideline assessed the efficacy and safety of omitting lymph node dissection in low-riskendometrial cancer patients, investigated the effect of sentinel lymph node mapping inearly-stage endometrial cancer surger y, addressed the outcome of chemoradiation therapy asa postoperative treatment in patients with advanced (stage III–IVA) endometrial cancer, andexplored the impact of initial treatment with immune checkpoint inhibitors on sur vival inpatients with advanced or recurrent endometrial cancer patients.
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort tostandardize and enhance the quality of domestic uterine corpus cancer treatment bydeveloping updated clinical practice guidelines in 2021. The KSGO revised the guidelinesbased on a literature search using 4 key elements: Population, Inter vention, Comparison,and Outcome framework. These elements include the evaluation of the efficacy and safety ofimmune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patientswho have failed platinum-based chemotherapy, as well as the effect of combined treatmentwith trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally,the guideline assessed the efficacy and safety of omitting lymph node dissection in low-riskendometrial cancer patients, investigated the effect of sentinel lymph node mapping inearly-stage endometrial cancer surger y, addressed the outcome of chemoradiation therapy asa postoperative treatment in patients with advanced (stage III–IVA) endometrial cancer, andexplored the impact of initial treatment with immune checkpoint inhibitors on sur vival inpatients with advanced or recurrent endometrial cancer patients.